Know Your Risk, Know Your Options
Abnormalities, or mutations, in the genes BRCA1 and BRCA2 can cause hereditary breast and ovarian cancer syndrome (HBOC), a cancer predisposition syndrome.
Mutations in these genes are rare and account for only a small percentage of cancers; about 5-10% of all breast cancers and 10-15% of ovarian cancers. Individuals with mutations in these genes, however, are at a significantly increased risk for developing breast, ovarian, and other cancers than those in the general population.
In families with HBOC syndrome, there is typically a pattern of early onset breast cancer (before the age of 50 or premenopausal).
Additionally, the family history may show more than one primary breast cancer in an individual, breast cancer in two or more generations, breast cancer in a male relative, and ovarian cancer, with or without a breast cancer diagnosis. Females with a BRCA1 mutation have a 50-85% risk of developing breast cancer and up to a 44% risk of developing ovarian cancer. Females with a BRCA2 mutation have a 40-70% risk of developing breast cancer and up to a 27% risk of developing ovarian cancer. Males with a BRCA1 or BRCA2 mutation can have up to a 5-10% lifetime risk for male breast cancer and an elevated risk of prostate cancer. Additionally, both males and females with BRCA1 or BRCA2 mutations may be at elevated risks for other cancers. Individuals with a mutation in the BRCA1 or BRCA2 gene have a 50% risk of passing on the mutation to their children.
What is the advantage of BRCA testing?
Genetic testing for the BRCA1 and BRCA2 pathogenic variants —through a blood sample—can provide further information about your risk for developing breast, ovarian or other cancers. Knowing more about your risk allows you to work with your healthcare provider to develop a monitoring and treatment plan.
- Increased surveillance for ovarian, breast and related cancers
- Using breast MRI in addition to mammography
- Risk-reducing medications
- Preventive surgery
- Lifestyle Modifications
- Education and risk assessment for family members
BRCA screening is performed through our sister laboratory, EGL Genetics Eurofins.
EGL Genetics has been providing superior, cutting-edge service for more than 47 years. Their expertise spans common and rare genetic disease testing, genomic variant interpretation, test development, and research. EGL Genetics is a CLIA-certified and CAP-accredited laboratory. They work with clients across the United States and from more than 45 countries to help improve patient diagnosis.
Learn more about why NTD Eurofins has been the laboratory to trust for over 30 years.Learn More
Our Goal is to Educate and Empower
Know your choices, understand your options, and talk you your healthcare provider about the best prenatal screening program for you.Learn More